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ABSTRACT 
 
Novel Functions for the Pregnane X Receptor include Regulation of mRNA Turnover 
and Involvement in Colon Cancer Progression. (August 2010)  
Navada Lorraine Eagleton, B.S., Texas A&M University 
Chair of Advisory Committee: Dr. Yanan Tian 
 
 To understand the mechanisms of transcriptional regulation of PXR, we 
performed yeast two-hybrid screenings to search for PXR-interacting proteins in a 
human liver cDNA library using the PXR ligand binding domain as the bait.  More than 
one million independent clones were screened. One positive clone was a partial cDNA 
of CNOT2 (amino acid 183-540). CNOT2 is a component of CCR4-NOT that is a multi-
subunit protein complex highly conserved from yeast to humans.  
Using a mammalian two-hybrid system in CV-1 cells and GST-pull down assays, 
we confirmed the direct interaction between PXR and CNOT2 and mapped the specific 
domains of association. In HepG2 cells, over expression of CNOT2 suppressed the 
PXR-regulated luciferase reporter gene activity.  siRNA knockdown of CNOT2 
potentiated PXR-transcriptional activity. These results strongly suggest that the CCR4-
NOT complex is significantly involved in transcriptional regulation of PXR.  
The immuno-precipitated CNOT2 complex contained deadenylase activity as 
determined by an in vitro RNA decay assay. The presence of transfected PXR inhibited 
the cNOT2-associated deadenylase activity, as demonstrated by poly(A) tail PCR. 
Cellular localization of PXR and cNOT2 by immuno-fluorescence microscopy indicates 
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that the interaction might occur within Cajal Bodies. Taken together, these results 
suggest that PXR regulates the mRNA turnover through direct interaction with the 
NOT2 component of the CCR4-NOT complex. 
PXR is also involved in colon cancer progression. Our results indicate that the 
evolutionarily conserved PXR protects organisms from carcinogenesis by inhibiting 
tumor growth as well as eliminating carcinogenic substances. Our laboratory proposes 
that pregnane X receptor has an important role in maintaining the balance of cells 
progressing through the cell cycle. In vitro and in vivo experiments demonstrate 
expression of PXR in colon cancer cells slows the progression of tumor formation. 
Colony growth of the PXR-transfected HT29 cells was suppressed in soft agar assay.  
In the xenograft assay, the tumor size formed in nude mice was significantly 
suppressed in HT29 cells stably transfected with PXR (310 mg±6.2 vs. 120 mg±6, 
p<0.01). The number of Ki-67 positive cells were significantly decreased in PXR-
transfected HT29 xenograft tumor tissue compared vector-transfected HT29 controls 
(p<0.01) as determined by immuno-histochemistry suggesting that PXR inhibits 
proliferation of colon cancer cells.  Results of flow cytometry analysis indicated that 
PXR-transfection in HT29 cells caused G0/G1 arrest. The growth inhibitory effects of 
PXR are likely mediated through the E2F/Rb-regulated check point since E2F1 nuclear 
expression was significantly inhibited by PXR over expression.  
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INTRODUCTION AND BACKGROUND 
 
Central to our understanding of xenobiotic/drug metabolism and avoidance of 
adverse drug responses including drug-drug interaction is to delineate the underlying 
mechanisms of how drugs are metabolized and the cofactors that modulate this activity. 
The importance of understanding the effects of combinations of chemicals has increased 
due to current therapeutic treatments and the ever changing chemical environment 
produced from the growing human population. Complications that arise from drug-drug 
interactions can result in decreased clinical efficacy of the drugs or increase toxicity. 
Adverse drug reactions are the 4th largest cause of mortality in the western world (Plant, 
2007). It is crucial to understand chemical interactions and drug-drug interactions to 
accurately predict human biological responses. Regulation of diseases requires the 
balance of activating and inhibiting various transcription factors. Therefore, it is very 
important that the study of the relationships among genetic polymorphisms, cancer 
susceptibility, environmental exposures and toxicity strive to achieve a comprehensive 
understanding of these complex mechanisms and the associated implications for 
prevention and treatment of human disease. The molecular pathways that govern disease 
are coordinately regulated by some of the same processes involved in metabolism and 
clearance of internal and external chemicals in the human body.  
 
 
This thesis follows the style of British Journal of Cancer. 
 
 
2 
Drug metabolism and detoxification    
Expression of drug metabolizing enzymes is highly adaptable in response to 
inducing compounds. Protein levels increase or decrease in response to exposure of 
chemical agents. Understanding these molecular mechanisms helps to predict xenobiotic 
interactions that could potentially have toxic effects. Nuclear receptors are responsible 
for communications from an internal or external chemical stimulus to target genes 
required to metabolize or expel the compound from the body. The role of nuclear 
receptors has evolved from their prototypic function in bacteria to a more complex 
version in humans and higher mammals.  
In general, drug metabolism and detoxification begins with a nuclear receptor 
responding to specific ligands that result in translocation to the nucleus and induction of 
the target gene by binding to drug response elements. Once the target gene is expressed 
its corresponding enzyme can bind the substrate and begin metabolism. Phase I and 
Phase II enzymes usually act together to metabolize the compound and ready it for 
excretion. However, Phase II of metabolism/detoxification is not always preceded by 
Phase I (Klaassen and Watkins, 2001).  Both groups of enzymes can be found in 
microsomes in the endoplasmic reticulum, the organelle responsible for protein and lipid 
maintenance.  However many Phase I and Phase II enzymes can be found in the cytosol 
or mitochondria. (See Table 1 and 2 for a complete list of enzymes and their cellular 
locations.) Cytochrome P450 enzymes, or CYPs, are Phase I drug metabolizing 
enzymes.  Cytochrome P450 enzymes act through hydrolysis, reduction, and/or 
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oxidation making the compound more polar and ready for action by Phase II DMEs 
(Klaassen and Watkins, 2003). 
 
TABLE 1: Phase I biotransformation of xenobiotics. These enzymes are responsible for 
Phase I biotransformation of xenobiotics and can be found in various cellular locations. 
Reactions Enzymes Locations 
Hydrolysis Esterase Microsomes, cytosol, lysosomes, blood 
 Peptidase Blood, lysosomes 
 Epoxide hydrolase Microsomes, cytosol 
Reduction Azo- and nitro- reductase Microflora, microsomes, cytosol 
 Carbonyl reductase Cytosol, blood, microsomes 
 Disulfide reductase Cytosol 
 Sulfoxide reductase Cytosol 
 Quinone reductase Cytosol, microsomes 
 Reductive dehalogenase Microsomes 
Oxidation Alcohol dehydrogenase Cytosol 
 Aldehyde dehydrogenase Mitochondria, Cytosol 
 Aldehyde oxidase Cytosol 
 Xanthine oxidase Cytosol 
 Monoamine oxidase Mitochondria 
 Diamine oxidase Cytosol 
 Prostaglandin H synthase Microsomes 
 Flavin-monooxygenase Microsomes 
 Cytochrome P450s Microsomes 
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Phase II drug metabolizing enzymes detoxify chemicals through conjugation, 
glucuronidation, sulfation, acetylation, and/or methylation and this makes the compound 
more water soluble and ready for excretion (Klaassen and Watkins, 2003).  
 
TABLE 2: Phase II biotransformation of xenobiotics. These enzymes are involved in 
Phase II biotransformation of xenobiotics and are found in various cellular locations.  
Reaction Enzymes Locations 
Glucuronide conjugation UDP-glucuronosyltransferases Microsomes 
Sulfate conjugation Sulfotransferases Cytosol 
Glutathione conjugation Glutathione S-transferases Cytosol, microsomes 
Amino acid conjugation Acyl-CoA:amino acid N-acyltransferase Mitochondria, microsomes 
Acylation Arylamine N-acetyltransferases Mitochondria, Cytosol 
Methylation Methyltransferases Cytosol, microsomes, blood 
 
 
 
Metabolism and detoxification of endogenous and exogenous compounds is a 
necessary biological process; unfortunately many of the exogenous compounds that 
require metabolism also become metabolically activated to give carcinogens.  
Pregnane X receptor and nuclear receptor super family   
The pregnane X receptor (PXR, NR1I2, also known as steroid X receptor (SXR) 
in humans) is an evolutionarily conserved receptor that belongs to the nuclear hormone  
 
 
 
 
 
5 
receptor (NR) superfamily. PXR was first cloned in mice by the Kliewer lab in 1998 
(Kliewer et al, 1998). Since then PXR homologs have been verified in rats, dogs, cows, 
primates, humans and zebrafish (NCBI Homologene). The nuclear receptor superfamily 
is the largest family of ligand-activated transcription factors; in total there are 48 NRs in 
humans (Zhang et al, 2004). [Table 3] It must be noted that members belonging to the 
nuclear receptor superfamily are not the only transcription factors responsible for 
regulating CYP enzymes. Another important group of transcription factors are those 
belonging to the basic helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) DNA binding motif 
family. The aryl hydrocarbon receptor (AhR) and its partner aryl hydrocarbon receptor 
nuclear translocator (ARNT) are bHLH/PAS transcription factors. The AhR-ARNT 
heterodimer is responsible for transcriptional regulation of cytochrome P450 1A1 
(CYP1A1), a protein that metabolizes many environmental toxicants, such as polycyclic 
aromatic hydrocarbons (PAHs), aromatic amines and heterocyclic amines. 
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TABLE 3: Human nuclear receptors. These proteins respond to respective ligands and 
initiate expression of proteins responsible for many biological processes including drug 
metabolism and detoxification (Robinson-Rechavi et al, 2001). 
Nuclear receptor Natural ligand Classical Nomenclature 
Thyroid hormone receptor α/β Thyroid hormone NR1A1, 1A2 
Retinoic acid receptor α/β/γ Vitamin A, related compounds NR1B1, 1B2, 1B3 
Peroxisome proliferator-activated receptor 
α, δ, γ 
Fatty acids, prostaglandins  NR1C1, 1C2, 1C3 
RAR-related orphan receptor α/β/γ Cholesterol NR1F1, 1F2, 1F3 
Liver X receptor α/β Oxysterol NR1H3, 1H2 
Farnesoid X receptor Oxysterol NR1H4 
Vitamin D receptor Vitamin D NR1I1 
Pregnane X receptor Pregnanes ,xenobiotics NR1I2 
Constitutive androgen receptor Androstane NR1I3 
Hepatocyte nuclear receptor-4 α/γ Fatty acids NR2A1, 2A2 
Retinoid X receptor α/β/γ Retinoids NR2B1, 2B2, 2B3 
Testicular receptor 2/4 N/A NR2C1, 2C2 
Estrogen receptors α/β estrogen NR3A1, 3A2 
Estrogen-related receptor α/β/γ Sex hormones NR3B1, 3B2, 3B3 
Glucocortoid receptor Cortisol NR3C1 
Mineralocorticoid Aldosterone NR3C2 
Progesterone receptor Progesterone NR3C3 
Androgen receptor Testosterone NR3C4 
Steroidogenic factor 1 Phospholipids NR5A1 
Nerve growth factor IB-like N/A NR4A1, 4A2, 4A3 
Germ cell nuclear factor N/A NR6A1 
DAX (dosage-sensitive reversal on X 
chromosome) 
N/A NR0B1 
 
 
Each nuclear receptor plays an important role in mammalian physiological functions by 
regulating transcriptional activity involved in processes including reproduction, 
differentiation, development, metabolism, metamorphism, and homeostasis 
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(Gronemeyer et al, 2004).  For example, PXR regulates these processes by inducing 
expression of multiple target genes upon ligand activation; including cyp2b, cyp3a, 
multidrug resistance transporter (mdr1), and cyp2c9 (Sahi et al, 2009). MDR1 is a Phase 
III drug transporter that protects cells from toxicity by quickly pumping drugs from the 
cells (Synold et al, 2001). All PXR-regulated genes products provide hepato-protection 
through drug metabolism and clearance. 
Most nuclear receptors have the same basic structure. [Figure 1]  The DNA 
binding domain (DBD) and ligand binding domain (LBD) are the major domains 
responsible for the transcriptional regulation activity of nuclear receptors. Located 
within the DBD are two cysteine coordinated zinc-fingers that are responsible for DNA 
binding and dimerization. The LBD is involved in receptor dimerization and interactions 
with co-regulators (Mohan and Heyman, 2003). Other regions important to the 
functionality of NRs include the transcriptional activation function 1 and 2 (A/B and F). 
These domains are located at the N-terminal and C-terminal regions respectively. The 
hinge domain is located between the DNA binding domain and ligand binding domain 
and functions to allow conformational changes. Upon ligand binding, nuclear receptors 
undergo conformational changes resulting in the release of co-repressors, recruitment of 
co-activators and the induction of transcription (Xu et al, 1999).  
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DC 
FIGURE 1: Nuclear receptor domains. The most important domains for the activity of a 
nuclear receptor are the DNA binding domain and the ligand binding domain. The DBD 
allows the nuclear receptor to act as a transcription factor and the LBD interacts with a 
wide range of endogenous and exogenous ligands. (Garcia et al, 2003) 
 
 
Compared to other nuclear receptors, PXR is extremely divergent across species 
(Ekins et al, 2008). Structure of the ligand binding domain varies greatly resulting in 
activation of PXR by different compounds in different species. For example, rifampicin 
is an extremely effective activator of human PXR but has little effect on mouse PXR; 
whereas the inverse is true for pregnenolone-16α-carbonitrile (PCN) (Ekins et al, 2007).   
Pregnane X receptor ligand activation 
PXR is a ligand-dependent transcription factor that is activated by a wide range 
of endogenous and exogenous compounds and substances. PXR was once considered to 
be an orphan nuclear receptor because at the time no natural ligand had been discovered; 
however 5β-pregnane-3,20-dione was found to naturally activate PXR (Mohan and 
Heyman, 2003). PXR is now considered an adopted nuclear receptor and PXR ligands 
are hydrophobic, small molecules. Human PXR ligands range from endogenous 
compounds such as bile acids (eg. lithocholic acid), many androstane/estrane steroids to 
exogenous compounds such as phenobarbital, clotrimazole, rifampicin, and vitamins like 
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vitamin D, β-carotene and herbal supplements such as hyperforin the active component 
in St. John’s wort (Ekins et al, 2007; Goodwin et al, 1999; Ekins and Erickson, 2002). 
After ligand activation, PXR heterodimerizes with retinoid acid receptor (RXR) 
and the complex translocates to the nucleus where it binds the xenobiotic response 
element (XRE) or xenobiotic response enhancer module (XREM) on the promoter of its 
target genes (Kliewer, 2003).  PXR-RXR binds to a recognition sequence on the target 
gene that consists of two half sites of AGGTCA arranged as either an everted repeat 
separated by six nucleotides (ER6) or a direct repeat separated by three (DR3) or four 
(DR4) nucleotides (Handschin and Meyer, 2003). Located within the distal enhancer 
region of CYP3A4 are two ER6-type PXR response elements located -7738bp to -
7717bp and -7698 to -7682. [Figure 2]  Nuclear receptor binding sites typically have 
high levels of promiscuity because the binding site is not specific for one receptor. For 
example, competitive binding is seen between PXR and CAR. Both can bind the same 
xenobiotic response elements on CYP2B and CYP3A genes; however, there is a clear 
ligand preference for activation of either nuclear receptor to the corresponding 
preferential target gene (Xie et al, 2000). 
 
 
 
FIGURE 2: Xenobiotic responsive elements of cyp3a4 gene. Consensus sequences 
within the promoter and enhancer regions of cyp3a4 are responsible for nuclear receptor 
binding and subsequent gene expression. (Handschin and Meyer, 2003) 
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Importance of cytochrome P450 enzymes 
The wide distribution of cytochrome P450s indicates that they are critical for 
survival. These enzymes existed in organisms prior to the divergence of eubacteria from 
eukaryotes, suggesting that these enzymes were responsible for important life functions 
long before animal-plant divergence (Nebert and Dieter, 2000). Cytochrome P450 
enzymes (CYPs) are Phase I drug metabolizing monooxygenases that are found in all 
organisms, ranging from bacteria to humans. Phase I enzymes are responsible for the 
biotransformation of endogenous and exogenous chemicals, typically by adding 
hydroxyl groups to the compound to make them more polar. There are 57 CYPs found in 
humans. All drug metabolizing enzymes have endogenous compounds as natural 
ligands, but are also responsible for metabolism of over-the-counter medications and 
pharmaceuticals. Drug metabolizing enzymes play a role in the synthesis and 
degradation of every known non-peptide involved in ligand-dependent transcriptional 
processes that affect growth, differentiation, apoptosis, homeostasis and neuroendocrine 
functions (Nebert and Dieter, 2000).  
For the metabolism of xenobiotics in humans, the most notable gene target is the 
cytochrome P450 3A family, which includes 3a4, 3a5, 3a7 and the recently identified 
3a43 (LeCluyse, 2001; Luo et al, 2004). Isoform protein expression levels vary greatly 
between individuals due to environmental and genetic differences that have been 
accentuated over thousands of years of human evolution (Thummel and Wilkinson, 
1998). Most cytochrome P450 genes are present in clusters on chromosomes, probably 
originating from gene duplications or other chromosomal alteration events. Human 
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cyp3a is found on chromosome 7 location 7q21-.1 arranged in order 3a4, 3a7, 3a5. 
[Figure 3]  Each  protein variant that is produced is composed of 13 exons forming 
approximately a 2 kb transcript (Finta and Zaphiropoulus, 2000).  
 
 
FIGURE 3: Cytochrome P450 3a gene cluster and transcripts. The cyp3a gene produces 
four protein isoforms each consisting of 13 exons. Cyp3a also contains three pseudo 
genes. (Finta and Zaphiropoulus, 2000) 
 
 
CYP3A5 expression is limited to only one fourth of human livers; protein levels 
are about the same or slightly higher than 3A4 in populations that express both isoforms 
(Krusekopf et al, 2003). CYP3A7 is the predominant form found in fetal liver; however, 
expression decreases rapidly after birth in an inverse relationship to 3A4 (Plant, 2007). 
CYP3A7 also is highly expression in endometrial and placental tissue, possibly 
indicating a mechanism of fetal protection (Sim et al, 2005). Cyp3a43 was recently 
cloned in 2001 and is expressed at low levels with low metabolic activity (Daly, 2006). 
Krusekopf et al. (2003) demonstrated that most substrates of CYP3A4 can be 
metabolized by the other 3A isoforms, but for most substrates CYP3A4 has higher 
metabolic activity.  
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CYP3A4 is the most abundant drug metabolizing enzyme in the liver. Over 50% 
of clinical drugs are subject to metabolism by this enzyme (Kolars et al, 1994). 
Expression of proteins involved in drug metabolism and detoxification have been found 
in skin, lung, nasal mucosa, eye, gastro-intestinal tract, kidney, adrenal gland, 
lymphocytes, pancreas, spleen, heart, brain, testis, ovary, placenta, plasma, erythrocytes, 
platelets and aorta (Gram, 1980; Farrell, 1987; Klotz, 1994). 
Protein-protein interactions 
The recent focus of our laboratory has been identifying novel roles for the 
pregnane X receptor or PXR, an important transcriptional regulator of drug metabolism. 
For example, our group has demonstrated- (1) PXR interacts with PRMT1 to regulate 
histone methylation (Xie et al, 2009), (2) PXR is involved in mediating DNA repair 
inflicted from ultraviolet light and benzo(a)pyrene (Naspinski et al, 2008), (3) PXR 
regulated pathways that interact with the inflammatory mediator NF-κB resulting in 
suppression of drug metabolizing enzyme activity (Xie and Tian, 2006; Gu et al, 2006). 
To further analyze the PXR interacting protein factors, we performed yeast two hybrid 
assays using PXR-ligand binding domain as the bait. After screening over a million 
clones from the human cDNA liver library we identified a partial clone of component 
NOT2, part of the CCR4-NOT complex, as an interactive partner of pregnane X 
receptor. The research in this thesis continues to expand the role of PXR regulation 
beyond drug metabolism to encompass functions of RNA regulation and mRNA 
turnover through interactions with the human CCR4-NOT complex.  
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Our laboratory has also identified a role for PXR in colon cancer progression. 
PXR is actively involved in tumor promotion and progression by affecting pathways 
involved in not only carcinogen detoxification but also associates with cell cycle check 
point proteins and factors involved in tumor invasion and metastasis. Novel 
physiological functions of PXR have been reported indicating that PXR plays roles in 
physiological and patho-physiological processes extending beyond metabolism and 
detoxification of xeno/endobiotics.  These novel functions are likely based on cross-talk 
mediated through protein-protein interactions.  The results presented in this thesis and 
previous publications from our laboratory demonstrate that the PXR is a dynamic multi-
functional nuclear receptor that is involved in many biological processes beyond its 
primary role in drug metabolism. 
CCR4-NOT is a multi-protein complex 
CCR4-NOT was one of the most intriguing PXR interactive partners identified in 
the human liver cDNA library screens. An evolutionary conserved complex, CCR4-NOT 
is present in most eukaryotic cells. In Saccharomyces cerevisiae, CCR4-NOT is the 
primary complex responsible for mRNA modification and degradation (Cuthbertson and 
Blackshear, 2008). There are two major forms of the complex- a 1.0 MDa complex and a 
1.9 MDa complex (Denis and Chen, 2003). The masses of the complex vary due to 
protein factors associating with CCR4-NOT core components for many of its biological 
functions. The complex is composed of nine core protein subunits- CCR4, Caf1, Caf40, 
Caf130 and NOT1-5. [Figure 4] 
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FIGURE 4: CCR4-NOT complex. The multi-protein complex is composed of nine 
subunits. (Denis and Chen, 2003) 
 
 
Clear modulation of the complex provides various functions by allowing the 
different components to come into contact with their respective interacting partners. 
There is still debate as to whether the components of CCR4-NOT can act individually or 
only as a complex. In yeast it was shown that CCR4-Caf1 and NOT2-5 components 
compose two very distinct modules that are both physically and functionally separated, 
with NOT1 as the bridge that holds the complex together (Bai et al, 1999). NOT1 is the 
scaffolding protein and the only protein component that is necessary for formation of the 
complex (Cuthbertson and Blackshear, 2008). NOT2 and NOT3 are similar in structure 
and affect transcriptional activity through interactions with key transcription factors. 
NOT4 is an E3 ubiquitin ligase involved in protein degradation (Albert et al, 2000); and 
NOT5 interacts with TFIID affecting positioning on the promoter (Lenssen et al, 2007). 
The NOT components are primarily responsible for protein-protein interactions that 
positively or negatively affect regulation of gene expression, whereas CCR4, CAF1, 
CAF40 and CAF130 are responsible for RNA deadenylation.  
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Examples of the many roles of CCR4-NOT components include involvement 
with the exome, histones, oxidative phosphorylation, vacuole and cell wall by up or 
down regulation of genes involved in these processes (Azzouz et al, 2009). In HeLa 
cells, Garapaty et al. (2008) demonstrated that the CCR4-NOT complex can act as an 
activator through interaction with NRC-interacting factor NIF-1. Garapaty’s group 
demonstrated that CCR4-NOT mediates activation through association with the ligand 
binding domain of nuclear hormone receptors. NOT components function as 
transcriptional repressors through restricting TFIID access to the promoter (Cui et al, 
2008, Collart et al, 1993, 1994, 1996). Every component of the CCR4-NOT complex has 
a specific function based on its individual protein-protein interactions.  
RNA transcript deadenylation appears to be one of the most biologically 
significant roles for the CCR4-NOT complex. Components of the CCR4-NOT complex 
are involved in cell proliferation and apoptosis through interaction with the CDK 
inhibitor p27 and antiproliferative protein Tob, respectively, by modulating the rate of 
deadenylation (Morita et al, 2007; Miyasaka et al, 2008).  When HEK293T cells are 
depleted of CCR4 protein, the deadenylase activity of the complex is lost resulting in 
cell growth impairment due to an increase in p27 mRNA (Morita et al, 2007). 
Deadenylase activity of the complex is also decreased in NIH3T3 cells through 
interaction of CNOT1 with the antiproliferative protein Tob (Miyasaka et al, 2008). 
Aslam et al, found that the CCR4-NOT deadenylase subunits CNOT7/Caf1a and 
CNOT8/Caf1b have overlapping roles and modulate cell proliferation (Aslam et al, 
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2009). The NOT components do not exhibit deadenylase activity but can direct RNA 
regulation through their various interactive partners. 
Specific functions of CNOT2 
The second NOT component, CNOT2, is a 26 kDa protein and the smallest 
component of the CCR4-NOT complex. However, it plays an important role in 
maintaining proximity of components NOT3, NOT4 and NOT5 with the rest of the 
complex (Denis and Chen, 2003). Therefore, CNOT2 is also essential for the complex to 
function in its entirety. Experiments in yeast show that mutations within CNOT2 
dramatically affect cellular processes such as maintaining integrity of the exome, 
vacuole, and oxidative phosphorylation (Azzouz et al, 2009).  
CNOT2 is typically thought of as a repressor of transcriptional activity (Traven 
et al, 2005). NOT or negative on TATA indicates the NOT components can negatively 
regulate transcriptional activity at the promoter level. The NOT Box domain is primarily 
responsible for repression by CNOT2. However, repression by CNOT2 is greater than 
the NOT Box domain acting alone (Zwartjes et al, 2006). For example, CNOT2 
repression is enhanced when co-expressed with SMRT or NCoR in combination with 
HDACs (Jayne et al, 2006). CNOT2 makes contact with ADA2, a component of the 
SAGA complex which is involved in cellular stress responses, resulting in repression of 
SAGA-responsive genes (Russel et al, 2002). Shi and Nelson (2005) screened the human 
fetal brain cDNA library to find that CNOT2 and CDK11 interact with each other. 
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RNA processing 
The central dogma of molecular biology, first described by Francis Crick in 
1958, indicated that only one middle man was necessary to pass genetic information 
from step to step in gene expression. However, he also pointed out that the flow was 
only one-way. Proteins could not be transformed into nucleic acids in a reverse reaction. 
[Figure 5]  Ribonucleic acids (RNA) play the intermediate messenger between DNA and 
protein.  
 
FIGURE 5: Diagram of the central dogma of molecular biology 
 
When the human genome was decoded in 2000, scientists discovered that over 
95% of our genome was “junk DNA”; in other words it did not specifically encode for a 
protein. The majority of noncoding sequences are relics left from millennia old 
translocations, duplications and other chromosome alterations. However, the term junk 
DNA is becoming obsolete due to new evidence showing that the junk regions play a 
major role in gene regulation, specifically at the RNA level (Bernstein et al, 2001; 
reviewed in Shi, 2003). For example, in some cases RNA interference (RNAi) influences 
the outcome of translation by inactivating mRNA transcripts before they are able to 
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come into contact with a ribosome. These bits of RNA come from RNA duplexes that 
are spliced or diced. 
RNA modifications occur within the nucleus and the cytoplasm. After 
transcription the newly produced RNA transcript (pre-mRNA) is transported to Cajal 
bodies where modifications occur that will stabilize the transcript for transport into the 
cytoplasm where translation occurs (Rippe, 2007). The 5’ end is capped and 3’ poly(A) 
tail is added to stabilize the mRNA transcript. The poly(A) tail aides in stabilization by 
elongating the end of the transcript with repeated adenine nucleotides. This process 
keeps the 3’ end guarded from exonucleases that could possibly degrade the transcript 
before it reaches a ribosome for translation (Meyer et al, 2004). Deadenylation of the 3’ 
poly(A) tail of the of the mRNA transcript decreases stability, which makes the 
transcript easier to degrade by exonucleases. The CCR4-NOT complex has been shown 
to be actively involved in mRNA deadenylation; multiple assays exist to determine 
degeneration of the poly(A) tail (Meijer et al, 2007; Salles et al, 1999).   
 Cajal bodies (CBs) were named after the Spanish scientist Ramon Cajal who 
discovered nucleic foci while studying the neuron in the 1920s. Coilin is a structural 
protein found exclusively in Cajal bodies. An unconventional CCR4-Caf1 deadenylase 
complex was found to concentrate in CBs and shuttle to and from the nucleus (Wagner 
et al, 2007). Outside of the nucleus there are multiple structures involved in RNA 
modifications- gems, p-bodies, GW182 or Dcp-containing bodies.  P-bodies are 
important for RNA decay following protein synthesis; mRNA turnover is extremely 
important for regulating gene expression. Other cytoplasmic bodies function to remove 
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aberrant mRNA before translation to eliminate the risk of producing deleterious proteins. 
Cougot et al. (2004) showed that CCR4 protein colocalizes with Dcp16, which is active 
in mRNA decay. All data indicate that nuclear and cytoplasmic foci are extremely 
dynamic structures. They require ongoing transcription to form; when transcription or 
translation is inhibited these foci will dissolve. 
CCR4-NOT complex has a role in most biological processes due to the versatility 
of protein-protein interactions of the core components of the complex. CNOT2 and PXR 
directly interact to suppress transcriptional activity of PXR and to direct the protection of 
deadenylation of cytochrome P450 3A4 mRNA.  
Pregnane X receptor is involved in colon cancer 
Many endogenous and exogenous compounds become carcinogenic after 
metabolism and detoxification has occurred (Ekins et al, 2007).  PXR also has an innate 
role in normal liver cell regeneration and repair. Dai et al. (2008) showed that 
hepatocyte proliferation in PXR null mice was inhibited after partial hepatoectomy. 
Their results indicate that PXR is required for normal progression of liver regeneration 
by modulating lipid homeostasis and regulating hepatocyte proliferation. Increased 
expression of PXR may increase the detoxification capability of cancer cells resulting in 
an increased resistance to anticancer agents (Matic et al, 2007; Nittke et al, 2008; Chen 
et al, 2007) and PXR plays a role in sensitization of cells for apoptotic responses (Zhou 
et al, 2008). Even though these studies have conflicting results, it is clear that PXR has a 
role in cancer. The same processes that govern cell regeneration regulate tumor 
formation. 
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Multistage carcinogenesis 
Multistage carcinogenesis involves three main steps: initiation, promotion, and 
progression. The initiation step begins with a carcinogen coming into contact with the 
target system triggering a mutation in a target cell. This can occur through bioactivation 
of a potential carcinogen during metabolism by Phase I or detoxification by Phase II 
enzymes. It requires more than one type of insult to progress to cancer because the 
initiator is usually administered in low doses over a period of time. Knudson’s multiple 
hit hypothesis accounts for the different types of damage a cell can withstand before 
progressing from initiation to promotion to finally, cancer progression and tumor 
formation (Weinberg, 2006).  
For example, carcinogens are produced while cooking food. The charring or 
burning of food produces benzo(a)pyrene due to the combustion reaction that occurs at 
high temperatures.  Our bodies metabolize nutrients in food and also detoxify some of 
the ingested chemicals. Bioactivation of toxins can result in DNA adduct formation and 
also RNA and/or protein adducts. However, DNA adducts are most common. A bulky 
adduct causes mutations that may be incorporated into DNA sequence prior to 
replication. Each time the cell divides it will pass on the random mutation. Usually 
mutations occur in areas of noncoding DNA, but sometimes they occur in tumor 
suppressor genes or proto-oncogenes. Key tumor suppressor genes that have altered 
expression in a wide range of cancers include TP53, Rb, APC, and TGFβ.  Tumor 
suppressor genes keep normal cellular processes in check and are usually expressed at 
high levels. Proto-oncogenes are just the opposite; they promote cell growth and are 
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regulated directly or indirectly by tumor suppressor genes. Examples of oncogenes 
include RAS, MYC, AKT, and VEGF; these oncogenes have a major impact on tumor 
progression. Ultimately, multi-stage carcinogenesis is linked to the cell’s ability for 
detoxification because the body relies on clearance of carcinogens. 
Cancer progression 
 Many cellular pathways are involved in promoting tumor formation.  Cancer is 
primarily a disease of aberrant signaling, and hijacking of normal biological processes 
that are essential for maintaining balance between proliferation and apoptosis. Cancer 
progression requires a combination of events to occur for a cell to be transformed 
(Weinberg, 2006). (1) Insensitivity to anti-growth signals occurs when the cell no longer 
responds to proteins that would normally halt progression of the cell cycle, if check 
points were not passed. (2) The cell can also gain control of its own growth signals, in 
effect becoming self sufficient without chemical signals from other cells. (3) Evading 
apoptosis allows cells with mutations in tumor suppressing genes to continue to growth 
and divide.  (4) Mutations in genes involved in telomere maintenance can give cells 
limitless replicative potential.  (5) Continuous blood flow is necessary to nurture a 
growing mass of cells. Cancer cells seek out blood streams by controlling the process of 
angiogenesis. (6) Cells that have achieved some of the feats mentioned above may use 
their new abilities for transport and invasion to other tissues to start new cancer cell 
colonies; this is called metastasis. 
The eukaryotic cell cycle is regulated by a series of proteins that either inhibit the 
cycle or allow it to progress. There are check points before each step that closely 
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monitor DNA replication, intermittent cell growth and cell division. If the check point 
proteins sense any mistakes in the sequence, misalignment of required cellular 
machinery or incorrect pairing of chromosomes the cell cycle will arrest. Repair 
mechanisms are then activated before the cell cycle continues. E2F proteins and their 
interactive partner protein Retinoblastoma (pRb) regulate the flow of the cell cycle. E2F 
genes are minimally expressed during quiescence, the cell’s silent state, but are induced 
as the cell enters the cell cycle. There are eight E2F genes that encode nine protein 
species; these can be classified as transcriptional activators or repressors (Trimarchi and 
Lees, 2002). When E2F proteins are bound to pRb, or one of its homologs p107 and 
p130, cell cycle progression is halted. Upon phosphorylation of retinoblastoma, EF2 is 
released to induce entrance into either DNA synthesis or mitosis from a phase of sentient 
growth. [Figure 6] In every cell cycle there is essentially a coordinated switch from the 
repressive to activating E2Fs that enables activation of genes involved in DNA 
replication and cell cycle progression (laquinta and Lees, 2007).  
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FIGURE 6: E2F and Rb proteins regulate cell cycle progression. When Rb protein is 
bound to E2F protein the cell cycle is halted; upon Rb phosphorylation E2F is released 
and acts as a transcription factor to promote cell cycle progression. (Zhu et al, 2005) 
 
 
A series of chemokines stimulate phosphorylation of Rb/E2F, the cyclins and CDKs 
or cyclin-depedent kinases. The cyclin-CDK signaling is regulated by CDK inhibitors 
that are responding to cell cycle sensors during check points. The cell can induce 
apoptosis, programmed cell death, to prevent the cell from spreading future side effects 
produced from a cell cycle check point violation. Induction of apoptosis involves sensing 
cellular or environmental cues, leading to activation of intracellular signaling pathways. 
Activation of E2F-mediated transcription causes an increase in proteins involved in 
apoptosis (laquinta and Lees, 2007). The cell cycle is essentially an interconnected 
network of crosstalk pathways that respond to the environment to maintain homeostasis.  
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Pregnane X receptor’s primary function is to regulate transcription of its various 
target genes, genes that are involved in drug metabolism and detoxification.  Our 
laboratory has demonstrated that PXR protein regulates pathways involved in cancer 
progression. It is clear that receptor-regulated drug metabolism and detoxification can be 
causative of cancer in certain circumstances.  
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MATERIALS AND METHODS 
 
Chemicals and reagents 
DMSO, rifampicin, anti-FLAG M2 antibody, anti-FLAG M2-agarose affinity 
beads, anti-HA antibody and anti-HA agarose affinity beads were from Sigma. Isotype 
IgGs were from Santa Cruz Biotechnology (Santa Cruz, CA). Nitrocellulose membranes 
were from Bio-Rad. 
Cell culture 
HepG2, CV-1, Cos7 and HT29 cells were cultured in Dulbecco’s modified 
Eagle’s medium (HyClone, Logan, UT) supplemented with 10% fetal bovine serum 
(Sigma) and 1X antibiotic and antimycotic (Invitrogen, Carlsbad, CA). Cell lines were 
maintained at 37°C in 5% CO2. PXR-HepG2 and PXR-HT29 stable transfectants were 
created as described in 73. 
Plasmids 
Plasmids expressing GST-fused PXR fragments have been created in out 
laboratory. DNA sequences coding different PXR fragments were PCR-amplified and 
subcloned into pGEX-5X-3 expression vector (Amersham Biosciences). pACT, pBIND, 
and pG5-luc were purchased from Promega (Madison, WI) for the mammalian two-
hybrid assay. pBIND-PXR (Gal4-PXR) and pACT-CNOT2 were constructed by 
inserting PCR-amplified CNOT2 DNA sequence into pACT vector following the 
manufacturer’s recommendation (Promega).  
The expression vector for hPXR, pCI-hPXR was generated as follows: DNA 
fragment corresponding to the coding region of hPXR (amino acids 1–434) was 
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generated by reverse transcription-PCR using total RNA from HepG2 cells. For pCI-
PXR, the PCR primers were 5'-gggaattcccaccaggaggtgagacccaaagaaagctgg-3' and 5'-
ggggtcgacgcggccgtcagctactgtgatgccgaaca-3', designed based on published hPXR 
sequence. The PCR product was modified with EcoRI and NotI or with NotI and BamHI 
and cloned into the pCI-neo vector (Promega, Madison, WI). 
Transient transfection and luciferase assay 
Cells were seeded in the 12-well plates at about 30% confluence  and transfected 
with PXR (PXR-HepG2) or vector (Vector-HT29 or V-HT29) using Lipofectamine 
(Invitrogen, Carlsbad, CA) according to the manufacture’s protocol. After 6 hours, 
transfected cells were treated with either Rifampicin (RIF) or DMSO for 24 hours, then 
collected and assayed for luciferase activity, in triplicate. For luciferase assay, cells were 
washed with cold PBS twice and then incubated with reporter lysis buffer (Promega, 
Madison, WI) for 10 minutes, then collected with the lysis buffer and centrifuged. 10% 
of the supernatant was taken for the luciferase assay according to the manufacture’s 
manual. 
Yeast two-hybrid assay 
Yeast two-hybrid assay was performed using Yeastmaker Yeast Transformation 
System (Clonetech). AH109 competent cells were transformed with human liver library 
cDNAs and plasmid containing PXR-gal4 activation domain. Transformed yeast cells 
were plated on SD-Leu-Trp  and SD-Leu-Trp-Ade-His 100 mm plates and incubated at 
30 °C. Yeast colonies were counted at days 3 and 6. Transformation efficiency was 
calculated for each assay using PXR ligand binding domain as bait.  
 
 
27 
Co-immunoprecipitation 
HepG2 cells were washed with PBS and homogenized in the Co-IP lysis buffer 
(20 nM Hepes, pH 7.4, 125 mM NaCl, 1% Triton X-100, 10 mM EGTA, 2 mM 
Na3VO4, 50 mM NaF, 20 mM ZnCl2, 10 mM sodium pyrophosphate, 1 mM 
dithiothreitol, and 1 mM phenylmethsulfonyl fluoride). 1X complete protease inhibitor 
mixture (Sigma) was added before use. Cells were homogenized in the same (above) 
lysis buffer. After centrifugation (12,000 X g in a microcentrifuge at 4 °C for 15 
minutes), supernatant fractions were collected and incubated with antibodies and 
GammaBind Plus-Sepharose beads (Amersham Biosciences) for 2 hours at 4 °C on a 
rotary shaker. Corresponding isotype IgG was used as a negative control. The beads 
were washed 3 times, and the precipitated protein complexes were analyzed with 
Western blot. 
Mammalian two-hybrid assay 
The mammalian two-hybrid assay was performed using Checkmate Mammalian 
Two-Hybrid System (Promega). CV-1 cells were seeded in 12-well plates and transient 
transfected with pBIND-PXR, pACT-CNOT2, and pG5-luc. 12 hours after transfection, 
cells were treated with rifampicin (10 uM, for 48 hours), and luciferase activity was 
determined with Polarstar optima luminometer (BMG Laboratory). 
GST pull-down assay 
 [35S]Methionine-labeled PXR-LBD protein was generated with TNT-coupled 
Reticulocyte Lysate System (Promega) using the SP6 promoter-driven cDNA plasmid as 
the template. PCR-generated CNOT2 cDNA fragments were inserted in-frame into 
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pGEX-5X-s (Amersham Biosciences). The plasmids were expressed in E. coli (BL21), 
and fusion polypeptides were purified with glutathione-Sepharose 4B beads (Amersham 
Biociences) according to the manufacturer’s instruction. 20 µg of each fusion 
polypeptide (estimated by comparison with bovine serum albumin in an SDS-PAGE gel 
with Coomassie Blue staining) was incubated with 20 µL of radiolabeled PXR in a total 
volume of 200 µL of binding reaction buffer (20 mM Hepes pH 7.9, 1% Triton X-100, 
20 mM dithiothreitol, 0.5% bovine serum albumin and 100 mM KCl) for three hours at 4 
°C. After incubation, beads were washed three times with the same buffer without 
bovine serum albumin. The bound proteins were eluted by boiling in the SDS-PAGE 
sample buffer and resolved by 12% SDS-PAGE gel electrophoresis. The signals were 
detected by autoradiography. The input control was 2 µL of the radioactive PXR.  
Small interfering RNA 
 Two small interfering RNA-expressing plasmids were constructed by cloning the 
sequences targeting CNOT2 gene into pSilencer 5.1 plasmids according to the manual 
(Ambion). The targeting plasmids were created by inserting 5’-aatatgacaaattagaagaac-3’ 
(CNOT2 siRNA #1) and 5’-aacgaacattcacattaggga-3’ (CNOT2 siRNA #2). The siRNA 
plasmids and the scramble siRNA control were co-transfected with PXR-directed 
reporter plasmid pGL3-3A4-Luc (5) into PXR-HepG2 cells. The transfected cells were 
treated with rifampicin (10 uM, for 48 hours). Luciferase activity and CNOT2 protein 
expression were determined with luminometry and Western blotting, respectively. 
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Poly(A) tail PCR 
 Poly(A) tail polymerase chain reaction (PAT PCR) was performed to analyze the 
status of cytochrome P450 3A4 mRNA. RNA was harvested from HepG2 cells and 
PXR-HepG2 cells that were treated with 10 μM rifampicin or DMSO for 24 hours. 
cDNAs were produced by reverse transcriptase PCR kit using 1 μL oligo(dT) primers 
(500 μg/mL) and 1 μL poly(A) tail anchor primer (5’-gcgagctccgcggccgcgt12-3’).  PCR 
amplification of cDNAs using forward primer CYP3A4 specific (5’-
tggatcgcctgaggtcagga-3’) and poly(A) tail anchor as reverse primer produced a mixture 
of products with various poly(A) tail lengths. The PCR products were run on a 2% 
agarose gel and images were generated by KODAK Imaging Station. 
Western blot 
Western blot was performed to confirm the expression of PXR in transfected 
culture cells; as well as E2F1 and Rb expression in xenograft tumors. Cell lysates or 
homogenized tissue samples were boiled in a SDS loading buffer at 95 °C for 10 
minutes. Proteins were separated by SDS-PAGE with 10% or 8% polyacrylamide gel 
and then transferred to the trans-blot transmembrane (Bio-Rad, Hercules, CA). 
Membranes were blocked in 5% milk TBST buffer (Tris buffered saline with 0.1% 
Tween 20) overnight at room temperature. Immunoblotting was performed by exposing 
membrane to primary antibodies, PXR monoclonal antibody (R&D Systems, 
Minneapolis, MN) at dilution of 1:1000, PXR polyclonal antibody (Santa Cruz, CA) at 
dilution of 1:500 or Rb monoclonal antibody (Calbiochem, Gibbstown, NJ) at dilution of 
1:1000, E2F1 monoclonal antibody (sc-251, Santa Cruz Biotechnology, Santa Cruz, CA) 
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at dilution of 1:1000, CNOT2 monoclonal antibody (antibody produced by Tian lab) at 
dilution 1:500 for over 2 hours and to corresponding secondary alkaline phosphatase 
(AP) conjugated antibodies (1:2000) for 2 hours. The presence of the respective protein 
was exposed by adding Western blot AP substrate (Promega, Madison, WI) according to 
the manual until stopping the reaction in cold tap water. 
Soft agar colony formation assay 
HT-29 cells with transfected vector or PXR were mixed with culture medium 
containing 0.25% agarose and plated at a density of 2 × 104 per well on the pre-solidified 
bottom layers of the same medium containing 0.5% agarose in 6 Petri dishes (60-mm). 
Cells were incubated at 37 °C. After 1 week 1 ml culture medium was added upon the 
solidified top layer. Photos were taken of all the Petri dishes after 3 weeks of incubation. 
The number and size of colonies with a diameter above 100 µm were determined by 
ImageJ program (NIH). The results were expressed as mean±SEM. 
Flow cytometry 
Cells transfected with PXR or vector were cultured up to 70% confluency, 
treated with DMSO or rifampicin for 24 hours and harvested by trypsinization. Cells 
were fixed in 70% ethanol for 2 hours, followed by washing with PBS twice and 
resuspended in Propidium iodide (20 µg/ml) staining solution containing 1 mg/ml RNase 
in 10 mM PBS (pH 7.4) for 30 minutes at room temperature. Flow cytometry analysis 
was performed immediately in an FACS Calibur flow cytometer (Becton Dickinson) 
with an excitation at 488 nm and an emission at 620 nm. Triplicate experiments were 
performed. 
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In vivo tumorgenesis assay 
Twenty-four female BALB/c nude mice, age 6 to 8 weeks, were divided into four 
groups. 7.5×106 HT-29 cells with transfected PXR gene or vector were subcutaneously 
injected into the nude mice at right flank, respectively. All animals received either corn 
oil or rifampicin (100 mg/kg/day intraperitoneal) treatment from day 6 to 16. The tumor 
size was measured by a vernier caliper every two days from day 6 to 16 after cell 
implantation. The volume was calculated by a formula: V=0.5a × b2, where “a” is the 
long diameter and “b” is the short diameter. The animals were sacrificed at day 16.  The 
tumor was removed, weighed and cut into two pieces. One piece was fixed with 4% 
neutral buffered formaldehyde solution and another one was frozen in liquid nitrogen for 
further assays.   
Immuno-cytochemistry 
To confirm the expression of transfected PXR in situ, immuno-cytochemical 
staining with PXR antibody was performed in cultured cells. PXR-HT29 and Vector-
HT29 cells were seeded in the 8-well chamber slides, cultured for two days and fixed 
with 4% neutral buffered formaldehyde solution for 20 minutes. Microwave heated 
antigen retrieval was performed in 0.01 mol/L citric acid buffer (pH 6.0) for 15 minutes. 
Cells were treated with 0.1% Triton X-100 for 10 minutes, then blocked with normal 
donkey serum for 30 minutes and then incubated with PXR mouse monoclonal antibody 
(R&D Systems, Minneapolis, MN) at dilution 1:100 overnight at 4°C. After washing 
with phosphate buffered saline containing 0.1% tween-20 (PBST), the biotinylated 
secondary antibody and the streptavidin-biotin complex (Invitrogen, Carlsbad, CA) were 
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applied, each for 30 minutes at room temperature with an interval PBST washing. 3,3'-
diaminobenzidine (Sigma, St. Louis, MO) solution (0.4 mg/ml, with 0.003% hydrogen 
peroxide) was used as a substrate for developing color. The slides were then 
counterstained with hematoxylin, dehydrated and mounted with coverslips. The results 
were visualized on an Olympus (AH-3, Olympus, Japan) microscope equipped with a 
SPOT INSIGHT COLOR digital camera, and images were obtained using SPOT 
DIGITAL CAMERA SYSTEMS software (Diagnostic Instruments, Inc., USA). 
Immuno-histochemistry 
Immuno-histochemical staining was performed in HT-29 tumors from nude 
mice. Paraffin-embedded sections were deparaffinized, rehydrated, and microwave 
heated for 15 minutes in 0.01 mol/L citric buffer (pH 6.0) for antigen retrieval. Then, 3% 
hydrogen peroxide was applied to block endogenous peroxidase activity. After 15 
minutes of blocking with normal serum (invitrogen, Carlsbad, CA), the primary antibody 
or corresponding control isotype IgG were applied and incubated overnight at 4°C. 
Slides were washed thrice with PBS, each for 5 minutes. The biotinylated secondary 
antibody and the streptavidin-biotin complex were applied, each for 30 minutes at room. 
After rinsing with PBS, the slides were immersed for 10 minutes in 3,3'-
diaminobenzidine (Sigma, St. Louis, MO) solution (0.4 mg/mL, with 0.003% hydrogen 
peroxide), monitored under microscope and stop the reaction with distilled water, 
counterstained with hematoxylin, dehydrated, and coverslipped. The primary antibodies 
used are as follows: ki-67 (sc-15402, Santa Cruz Biotechnology, Santa Cruz, CA), PXR 
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(PP-H4417-00, R&D Systems, Minneapolis, MN) and E2F1 (sc-251, Santa Cruz 
Biotechnology, Santa Cruz, CA). 
Immuno-fluorescence 
Paraffin-embedded sections were deparaffinized, rehydrated, and microwave 
heated for 15 minutes in 0.01 mol/L citric buffer (pH 6.0) for antigen retrieval. After a 
blocking with 10% donkey serum (Jackson ImmunoResearch, West Grove, PA) for 30 
minutes, the primary antibody solution containing mouse anti-PXR antibody (1:100) and 
rabbit anti-Ki-67 antibody (1: 100), or mouse anti-CNOT2 (1:250) and rabbit anti-PXR 
(1:500) or anti-coilin (1:500) or the solution of corresponding isotype control IgGs at the 
same concentration with primary antibody were applied and incubated overnight at 4°C. 
Sections were washed with PBS for 3 times, each for 5 minutes. The secondary antibody 
solution containing donkey anti-mouse antibody conjugated with orange-red fluorescent 
AF568 and donkey anti-rabbit antibody conjugated with green fluorescent AF488 (both 
from invitrogen, Carlsbad, CA and at dilution of 1:1000) was applied in dark for 30 
minutes. Slides were washed 3 times with PBS and mounted with aquatic medium 
contained DAPI. The primary antibodies used are as follows: anti-PXR from R&D 
Systems (Minneapolis, MN), anti-Ki-67 from Santa Cruz Biotechnologies (Santa Cruz, 
CA),anti-coilin from BD Biosciences (San Jose, CA) and mouse anti-CNOT2 which our 
lab produced. 
TUNEL staining 
Terminal deoxyribonucleotide transferase–mediated nick-end labeling (TUNEL) 
staining was done using the In situ Cell Death Detection kit (Roche Applied Science, 
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Indianapolis, IN) following the instructions of the manufacturer. Briefly, 4-µm-thick 
formalin-fixed, paraffin-embedded tissue sections were deparaffinized and rehydrated. 
Endogenous peroxidase activity was quenched by hydrogen peroxide and tissue protein 
was hydrolyzed with proteinase K. Positive control are sections treated with DNase I 
1,000 units/mL. Negative control sections are incubated with label solution (without 
terminal deoxynucleotidyl transferase enzyme). All other sections were incubated with 
TUNEL reaction mixture (fluorescein-labeled nucleotides) at 37°C for 1 hour in a humid 
chamber, incubated with converter-POD solution (antifluorescein antibody conjugated 
with POD) for 30 minutes at 37°C, treated with DAB, and counterstained with 
hematoxylin. 
Quantitative measurements 
The quantitative analysis of immuno-histochemical staining with nuclear positive 
(Ki-67, TUNEL, Rb and E2F1) was performed by PhotoShop and ImageJ (NIH) 
programs. 10 to 15 photos per sample were taken randomly. Briefly choose the positive 
staining by PhotoShop Color Range and save it as the criterion for all samples. Fill the 
chosen area with white color and fill the rest area with black color. Then the function of 
Analyze Particle in ImageJ Program was applied to count the number of positive nuclei. 
Statistics  
All data were analyzed by comparing means with One-Way ANOVA method 
and followed an additional Duncan Post Hoc test for the results of luciferase activity and 
cell cycle assay using SPSS (Version 11.5.0). Data was shown as mean ± SEM and P < 
0.05 denotes the presence of a statistically significant difference. 
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RESULTS 
 
Substudy 1: Pregnane X receptor interacts with CNOT2 of the CCR4-NOT 
complex 
Identification of PXR-LBD interactive partners by yeast two-hybrid assay  
PXR ligand binding domain (PXR-LBD) was inserted into pGBKT7 as the bait for 
yeast two-hybrid assay to screen the human cDNA liver library for interactive partners.  
Interactions were observed between PXR and many positive clones, including known 
PXR partner retinoic acid receptor β (RXRβ) and metastasis associated protein 1 
(MTA1). In total, over one million cDNA clones were screened with PXR-LBD as bait 
yielding one interactive partner of particular interest to our lab. One of the positive 
clones was a partial cDNA of CNOT2, amino acids 183-540. The cDNA fragment was 
extracted from yeast cells, inserted in pACT2 plasmid and transformed into AH109 yeast 
for confirmation testing with α-gal assay (Figure 7A) as well as yeast growth assay (7B). 
The results indicated that PXR ligand binding domain interacts with CNOT2 fragment. 
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FIGURE 7: Yeast two-hybrid assay revealed that CNOT2 may be an important 
interactive partner of PXR. α-gal assay and yeast growth assay were conducted to verify 
the initial results from the yeast two-hybrid assay. AH109 yeast colonies were plated 
onto SD-2 and SD-4 (with x-gal) 100 mm Petri dishes. The plates were incubated at 30 
°C for 3 days, then photographed. 
 
 
To characterize the interactive domains between PXR-LBD and CNOT2, PXR-LBD 
was inserted into pGBKT7 (bait vector). CNOT2 fragments corresponding to different 
domains were cloned into pACTs plasmid (prey vector). [Figure 8]  
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FIGURE 8: Engineered CNOT2 fragments used in yeast two-hybrid and GST pull down 
assays. 
 
 
The yeast were cotransformed with PXR-LBD bait and various fragments of 
CNOT2. The transformed yeast were plated on SD –Leu-Trp-X-α-gal media for α-gal 
assay (Figure 9A) as well as onto SD –Leu-Trp-Ade-His media for growth assay (9B). 
The conserved domain and the NOT Box domain interacted with PXR-LBD in yeast 
two-hybrid assay and growth assay. The other CNOT2 fragments showed little 
interaction with the PXR ligand binding domain. The NOT Box domain alone showed a 
greater interaction with PXR-LBD; but there was a synergistic interaction with both the 
conserved domain and the NOT Box.  
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FIGURE 9: PXR ligand binding domain interacts with specific domains of CNOT2. α-
gal assay and growth assays were performed with various fragments of CNOT2. CNOT2 
fragments were created by inserting into pACT vector. Plasmid interaction pSV40 with 
p53 was used as the positive control and pSV40 with pLaminC was used as the negative 
control. (Results were generated in collaboration with Liu Duan.) 
 
 
Mapping of CNOT2 domains involved in the interaction with PXR-LBD 
CNOT2 gene fragments (configured as in Figure 8) were fused to GST gene in order 
to produce GST-fusion peptides. The fusion peptides were expressed in E.coli and 
conjugated to glutathione beads. The GST pull-down protein complexes were separated 
by SDS-PAGE; and radioactive signals of 35S-labeled PXR and luciferase (negative 
control) were recorded by autoradiography (Figure 10A) and Coomassie blue stain 
(10B). Results from the GST pull-down confirm that PXR-LBD and CNOT conserved 
and NOT Box domains interact directly. 
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FIGURE 10: GST pull down confirms that PXR and CNOT2 directly interact. 
[35S]Methionine-labeled PXR-LBD protein was generated using the SP6 promoter-
driven cDNA plasmid as the template. PCR-generated CNOT2 cDNA fragments were 
inserted in-frame into pGEX-5X-s. The plasmids were expressed in E. coli (BL21), and 
fusion polypeptides were purified with glutathione-Sepharose 4B beads. 20 µg of each 
fusion polypeptide (estimated by comparison with bovine serum albumin in an SDS-
PAGE gel with Coomassie Blue staining) was incubated with 20 µL of radiolabeled 
PXR in a total volume of 200 µL of binding reaction buffer for 3 hours at 4 °C. After 
incubation, beads were washed three times. The bound proteins were eluted by boiling in 
the SDS-PAGE sample buffer and resolved by 12% SDS-PAGE gel electrophoresis (A). 
The signals were detected by autoradiography (B). The input control was 2 µL of the 
radioactive PXR. (Results were generated in collaboration with Liu Duan.) 
 
 
PXR and CNOT2 interact directly in mammalian cell lines  
PXR-LBD was fused with Gal4 DNA binding domain (DBD) in plasmid pBind 
(Gal4-PXR). CNOT2 was fused to activation domain (VP16) in plasmid pACT 
(Promega). Luciferase reporter gene driven by gal4 DNA binding consensus sequences 
was transiently co-transfected with Gal4-PXR and pACT-CNOT2 into CV-1 cells. The 
cells were treated with 5 μM rifampicin (RIF) 6 hours after transfection. Luciferase 
activity was measured 24 hours after transfection (Figure 11A). The results 
demonstrated that PXR and CNOT2 interact within CV-1 cells in a PXR ligand-
 
 
40 
dependent manner. There was no induction of luciferase activity without transfection of 
both Gal4-PXR and pACT-CNOT2.  
The interaction between CNOT2 and PXR was determined by co-
immunoprecipitation. Cos7 cells were transfected with HA-tagged CNOT2 and Flag-
tagged PXR plasmids. Cells were treated with 10 μM RIF or DMSO for twenty four 
hours after transfection. Cell lysate was precipitated by beads conjugated with HA or 
Flag antibody. Western blot was used to detect anti-Flag antibody (Figure 11B). 10% of 
the total lysate was loaded as the input. There was an increase in precipitated protein 
when treated with PXR ligand RIF. The results indicate that Flag-PXR was successfully 
precipitated with HA-tagged CNOT2 protein. 
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FIGURE 11: Mammalian two-hybrid and co-immunoprecipitation assays indicate that 
PXR and CNOT2 directly interact within mammalian cell lines. For the mammalian two-
hybrid assay CV-1 cells were seeded in 12-well plates and transient transfected with 
pBIND-PXR, pACT-CNOT2, and pG5-luc. 12 hours after transfection, cells were 
treated with rifampicin (10 uM, for 48 hours), and luciferase activity was determined 
(A). For the co-immunoprecipitaion assay HepG2 cells were co-transfected with Flag-
PXR and HA-CNOT2 plasmids. Cells were treated with 10 µM RIF for 48 hours before 
harvest. Transfected HepG2 cells were homogenized in lysis buffer, centrifuged to 
collect proteins and supernatant fractions were collected and incubated with antibodies 
and GammaBind Plus-Sepharose beads for 2 hours at 4 °C on a rotary shaker. 
Corresponding isotype IgG was used as a negative control. The beads were washed 3 
times, and the precipitated protein complexes were analyzed with Western blot (B) using 
an antibody against Flag-PXR. 10% of the supernatant collected before incubation with 
beads was used for the input. (Results were generated in collaboration with Liu Duan.) 
 
 
The interaction between CNOT2 and PXR suggests the CCR4-NOT complex 
regulates PXR-transcriptional activity  
 The effect of CNOT2 on the transcriptional activity of PXR was tested in 
HepG2 cells. HepG2 cells with constitutively expressed PXR were cotransfected with 
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PXR-driven luciferase reporter gene and pTargeT-CNOT2, mammalian expression 
vector under control of the CVM promoter. Cells were treated with rifampicin for 48 
hours before proteins were harvested for the luciferase assay. Relative luciferase activity 
indicates that PXR-regulated gene expression is suppressed when CNOT2 and PXR 
interact (Figure 12A). Relative luciferase activity was markedly decreased with CNOT2 
expression (p<0.01).  
PXR-HepG2 cells were transiently co-transfected with PXR-driven luciferase 
reporter gene, CNOT2 siRNA and scramble RNA as the negative control. Two siRNA 
sequences (CNOT2 siRNA #1 and CNOT2 siRNA #2) of 0.5 μg each were used for the 
knockdown. (Figure 12B) PXR was activated by treatment of 10 μM rifampicin and 
luciferase activity was measured 48 hours after transfection. We continued to use 
CNOT2 siRNA #1 sequence since it had the greatest silencing effect and 0.5 μg and 1.0 
μg of RNA were used to measure the knockdown effects (Figure 1C). siRNA CNOT2 
knockdown results in enhancement of PXR-transcriptional activity as indicated in PXR-
driven luciferase activity assay.  
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FIGURE 12: Transcriptional activity of PXR is suppressed by PXR-CNOT2 interaction. 
PXR-HepG2 cells were cotransfected with PXR-driven luciferase reporter gene and 
pTargeT-CNOT2, then treated with rifampicin for 48 hours. For luciferase assay, cells 
were washed with PBS and incubated with reporter lysis buffer for 10 minutes, then 
collected with the lysis buffer and centrifuged to collect proteins. 10% of the supernatant 
was taken for the luciferase assay. siRNA knockdown of CNOT2 was performed to 
determine the effect on PXR-transcriptional activity. Two small interfering RNA-
expressing plasmids (CNOT2 siRNA #1 and CNOT2 siRNA #2) were constructed by 
cloning the sequences targeting CNOT2 gene into pSilencer 5.1 plasmids. The siRNA 
plasmids and the scramble siRNA control were co-transfected with PXR-directed 
reporter plasmid pGL3-3A4-Luc into PXR-HepG2 cells. The transfected cells were 
treated with rifampicin (10 uM, for 48 hours). CONT2 siRNA #1 sequence had the 
greatest effect and was thus used for subsequent assays. Luciferase activity was 
determined with luminometry (B and C). The results were displayed as the folds of 
control group. (Results were generated in collaboration with Ke Sui.) 
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CYP3A4 RNA turnover is affected by PXR-CNOT2 interaction  
To analyze mRNA turnover activity and mRNA stability PAT PCR was 
performed. The diagram shows that a gene specific primer anneals to a set location and a 
poly(A) tail anchor primer can anneal anywhere on the length of repeated adenine 
residues (Figure 13A). The PAT PCR results indicate when there is co-transfection of 
CNOT2 and PXR, deadenylation of the poly(A)tail is less (Figure 13B). The smear seen 
in lanes containing PXR indicate there were many different lengths of PCR product; 
whereas the lanes without PXR have mostly the same length of product and therefore do 
not show a smear. There was little effect after treatment with the PXR ligand rifampicin 
(RIF). 
Cellular localization indicates PXR and CNOT2 interact within the nucleus of 
HepG2 cells 
To determine the location of PXR and CNOT2 protein immuno-fluorescent 
double staining was performed in HepG2 cells. The cells were treated with rifampicin 
(RIF) or DMSO for 24 hours. The upper panel of images is from HepG2 cells without 
PXR expression; the lower panel of images has PXR expression. The antibody against 
CNOT2 indicates that when PXR is over-expressed CNOT2 protein relocates closer to 
the nucleus (compare Figures 14A/C to 14E/G). No apparent differences were observed 
in cells treated with RIF. 
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FIGURE 13: Results indicate that PXR over expression prevent mRNA transcript degradation 
through poly(A) tail deadenylation. The schematic of poly(A) tail PCR (PAT PCR) shows that 
mRNA transcripts with variable poly(A) tail lengths were harvested from HepG2 or PXR-
HepG2 cells. . Total RNA was harvested from HepG2 cells and PXR-HepG2 cells that had been 
treated with 10 μM rifampicin or DMSO for 24 hours. cDNAs were produced by reverse 
transcriptase PCR using oligo(dT) forward primer and reverse primer that anchors to the poly(A) 
tail. PCR amplification of cDNAs using a CYP3A4 specific forward primer and poly(A) tail 
anchor as reverse primer produced a mixture of products with various poly(A) tail lengths. The 
CYP3A4 target product with extended poly(A) tail is approximately 360 bp. The PCR products 
were analyzed by gel electrophoresis  on a 2% agarose gel and images were generated by 
KODAK Imaging Station (B). 
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FIGURE 14: Immuno-fluroscent microscopy of HepG2 and PXR-HepG2 cells indicates 
that PXR and CNOT2 proteins may colocalizes within the nucleus. HepG2 and PXR-
HepG2 cells were treated with 10 µM rifampicin or DMSO for 24 hours. Cells were 
washed with PBS and fixed with 4% parafomaldehyde. Monoclonal antibody against 
CNOT2 (1:500) and polyclonal antibody against PXR (1:1000) were applied and 
incubated at room temperature for 24 hours.  Corresponding fluorescent secondary 
antibodies (anti-mouse green and anti-rabbit Alexia red) were applied and incubated at 
room temperature for 4 hours. DAPI mounting solution was applied and coverslips 
mounted.   
 
 
 An antibody against coilin was used to determine the presence of Cajal bodies 
within the nucleus. In general, we observed that there were fewer coilin foci present in 
HepG2 cells lacking PXR expression. (Figure 15A) The numbers of coilin foci were not 
altered by treatment with rifampicin. In Cos7 cells, GFP-PXR fusion protein was 
produced to pinpoint the precise location of PXR, instead of an over-expression vector 
that results in illuminating the entire nucleus (as in Figure 14F/H).Using the GFP setting 
on the fluorescent microscope we were able to visualize the GFP-PXR protein (Figure 
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15B). The cellular locations of coilin and GFP-PXR protein indicate that they might 
colocalize within the nucleus. 
 
 
 
FIGURE 15: Immuno-fluorescent microscopy indicates that expression of PXR increases the 
number of coilin foci. HepG2 and PXR-HepG2 were treated with DMSO and 10 µM rifampicin 
(RIF) for 24 hours. Cells were washed with PBS and fixed with 4% paraformaldehyde. 
Monoclonal mouse anti-coilin (1:500) was applied and incubated for 24 hours. Cos7 cells were 
transfected with engineered GFP-PXR plasmid that produce PXR protein with C-terminal green 
fluorescent protein. The presence of GFP was detected by OLYMPUS microscope. 
 
 
Substudy 2: Pregnane X receptor is involved in colon cancer progression 
Restoration of PXR by stable transfection of PXR gene in HT29 cells 
To investigate the effects of PXR on tumor cell growth we have restored the 
PXR expression through transfection of human PXR into colon cancer cell line. HT29 
cells with transfected vector are PXR negative (Fig 16A) whereas cells stably transfected 
with PXR exhibit over expressed PXR protein which is localized in the nucleus (Figure 
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16B) as determined by immuno-cytochemical staining. [Image to scale at 50 µm] The 
PXR regulated response was tested by co-transfection with PXR and its driven luciferase 
reporter gene. The relative luciferase activity was markedly increased 4-fold (p<0.01) 
after treatment with PXR ligand rifampicin (RIF) in PXR transfected cells (Fig 16C). 
 
 
FIGURE 16: Stabilization of PXR-HT29 cell line. To confirm the expression of 
transfected PXR in situ, immuno-cytochemical staining with PXR antibody was 
performed in cultured cells. PXR-HT29 and Vector-HT29 cells were seeded in the 8-
well chamber slides, cultured for two days and fixed with 4% neutral buffered 
formaldehyde solution for 20 minutes. Cells were blocked with normal donkey serum for 
30 minutes and then incubated with PXR mouse monoclonal antibody (at dilution 1:100) 
overnight at 4°C. After washing, the biotinylated secondary antibody and the 
streptavidin-biotin complex were applied, each for 30 minutes at room temperature. 3,3'-
diaminobenzidine solution was used as the substrate for developing color. The slides 
were then counterstained with hematoxylin, dehydrated and mounted with coverslips. 
The results were visualized on an Olympus microscope equipped with a SPOT 
INSIGHT COLOR digital camera (A and B). Luciferase assay was conducted to 
measure PXR-transcriptional activity to determine if the PXR transfected gene is 
functioning normally. HT29 cells were transfected or cotransfected with pGL3-3A4-luc 
reporter gene and/or pCl-NEO-PXR, respectively. Cells were treated with rifampicin (10 
µM for 48 hours) before proteins were harvested for the luciferase activity assay. 
(Results were generated in collaboration with Nengtai Ouyang.) 
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PXR inhibited cell proliferation and anchorage-independent colony formation of 
HT29 cells   
 Upon expression of PXR through stable transfection, we noted cells transfected with 
PXR grew slower as compared to Vector-HT29 cells. To further characterize the tumor 
suppressive effect of PXR, we performed anchorage-independent growth assay in soft 
agar culture (Figure 17B and 17C). The presence of PXR in these cells significantly 
inhibited colony formation by 34% (399.7±26.7 vs. 264.0±21.1, p<0.01, Figure 17A) 
after 3 weeks in culture. Treatment with the PXR ligand rifampicin did not change cell 
growth and colony formation as compared to the DMSO control (data not shown). 
 
 
FIGURE 17: Soft agar colony formation assay indicates that the number of cells is less 
in PXR-HT29. HT-29 cells with transfected vector or PXR were mixed with culture 
medium containing 0.25% agarose and plated on 60 mm Petri dishes containing 0.5% 
agarose. Cells were incubated at 37 °C. All dishes were photographed after 3 weeks. The 
number and size of colonies with a diameter above 100 µm were determined by ImageJ 
program (NIH). The results were expressed as mean±SEM. (Soft agar assay conducted 
by Ke Sui) 
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Restoration of PXR expression inhibited tumor growth in vivo   
To further analyze the growth inhibitory effects of PXR, Vector-HT29 and PXR-
HT29 cells were injected subcutaneously into nude mice. The tumors that formed were 
removed at 17 days (Figure 18A). The tumor volume calculated by both long diameter 
and short diameter in PXR-HT29 group was significantly smaller than that in Vector-
HT29 group (Corn oil treated: 173 mm3 ± 18 vs. 441 mm3 ± 78, p<0.05; RIF treated: 
164 mm3 ± 18 vs. 396 mm3 ± 84, p<0.05) at day 16 (Figure 18B).  The tumors were 
removed from mice upon the termination of the experiments. Figure 3B shows 
representative tumors from vehicle treated animals. The final tumor weight shows a 
significant difference between Vector-HT29 and PXR-HT29 groups (Corn oil treated: 
485 mg ± 69 vs. 223 mg ± 37, p<0.01; RIF treated: 471 mg ± 73 vs. 190 mg ± 32, Figure 
18C) but RIF treatment did not produce any effect.  
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FIGURE 18: In vivo tumorgenesis model indicates growth is inhibited in tumors with 
PXR expression. Twenty-four female BALB/c nude mice, age 6 to 8 weeks, were 
divided into four groups. 7.5×106 HT-29 cells with transfected PXR gene or vector were 
subcutaneously injected into the nude mice at right flank. All animals received either 
corn oil or rifampicin (100 mg/kg/day intraperitoneal) treatment from day 6 to 16. The 
tumor size was measured by a vernier caliper every two days from day 6 to 16 after cell 
implantation; the volume was calculated. The animals were sacrificed at day 16, tumors 
removed, weighed and preserved. (Results were generated in collaboration with Nengtai 
Ouyang, Ke Sui, Ying Xie and Hongmei Cui.) 
 
 
Immuno-histological analysis of suppression of proliferation by PXR in xenograft 
tumor tissues 
To determine the mechanism of PXR-dependent inhibition of tumor growth in 
nude mice, we first measured cellular proliferation and apoptosis by immuno-
histochemistry, immuno-fluorescent double staining and terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) staining in these tumor tissues (corn oil 
treated tumors only). Over expression of nuclear PXR protein is retained in most tumor 
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cells from the PXR-HT29 xenografts but not in Vector-HT29 tumors (Figure 19A and 
19B). The cell proliferating marker Ki-67 is positive in the nucleus of cancer cells 
(Figure 19C and 19D). The number of Ki-67 positive cells per field (a photo at 400× 
magnification) is significantly lower in PXR-HT29 group than in the Vector-HT29 
control group (50.13±4.96 vs. 30.47±5.19, p<0.01, Figure 19H). The TUNEL staining 
shows positive with brown color in the scattered single cells and apoptotic bodies 
(Figure 19E and 19F) in all tumor samples. The positive cells were counted by ImageJ 
program; however, there was no statistically significant differences in the number of 
apoptotic cells between these two groups (5.79±0.57 vs. 5.03±0.53, p>0.05, Figure 19I). 
Furthermore, the immuno-fluorescent double staining with Ki67 and PXR showed a 
mutually exclusive distribution pattern (Figure 19G).  
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FIGURE 19: Analysis of xenograft tumor tissues indicates cells are less proliferative in PXR positive 
samples but apoptosis is not affected. Terminal deoxyribonucleotide transferase–mediated nick-end 
labeling (TUNEL) staining was performed on HT29 and PXR-HT29 cells (E and F). 4-µm-thick formalin-
fixed, paraffin-embedded tissue sections were deparaffinized and rehydrated. Positive controls are sections 
treated with DNase I 1,000 units/mL. Negative control sections are incubated with label solution (without 
terminal deoxynucleotidyl transferase enzyme). All other sections were incubated with TUNEL reaction 
mixture (fluorescein-labeled nucleotides) at 37°C for 1 hour, incubated with converter-POD solution 
(antifluorescein antibody conjugated with POD) for 30 minutes at 37°C, treated with DAB, and 
counterstained with hematoxylin. Cells stained positive for apoptosis are dark colored. For immuno-
fluroescence double staining (Figure 19G)HT29 and PXR-HT29 cells were blocked with 10% donkey 
serum for 30 minutes, the primary antibody solution containing mouse anti-PXR antibody (1:100) and 
rabbit anti-Ki-67 antibody (1: 100) or the solution of corresponding isotype control IgGs at the same 
concentration with primary antibody were applied and incubated overnight at 4°C. Sections were washed 
with PBS for 3 times, each for 5 minutes. The secondary antibody solution containing donkey anti-mouse 
antibody conjugated with orange-red fluorescent AF568 and donkey anti-rabbit antibody conjugated with 
green fluorescent AF488 was applied in dark for 30 minutes. Slides were mounted with aquatic medium 
contained DAPI. (Immuno-histochemistry conducted by Ouyang Nengtai) 
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PXR expression in colon cancer cells leads to G0/G1 cell cycle arrest  
To explore the mechanism of the growth suppressive effects of PXR in HT29 
cells, a cell cycle analysis was performed by staining with propidium iodide and 
performing flow cytometry. Arrest of cell cycle progression contributes to the inhibition 
of tumor cell growth. The results showed that the percentage of cells at G0/G1 phase is 
significantly higher in PXR-HT29 cells than in Vector-HT29 cells (67.2%±1.9 vs. 
40.5%±1.4, p<0.01) and the percentage of the cell population at S phase and G2/M 
phase is significantly lower in PXR-HT29 cells than in Vector-HT29 cells, (25.2%±0.6 
vs. 43.6%±1.2, P<0.01, 15%±2.5 vs. 7.6%±0.6, p<0.01). (Figure 20) However, PXR 
ligand rifampicin did not change the cell cycle distribution as compared to the DMSO 
control group. 
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FIGURE 20: Results from flow cytometry indicate a G0/G1 arrest in PXR-HT29 cells. 
Cells transfected with PXR or vector were cultured up to 70% confluency, treated with 
DMSO or rifampicin for 24 hours and harvested by trypsinization. Cells were fixed in 
70% ethanol, washed in PBS and resuspended in Propidium iodide (20 µg/ml) staining 
solution. Flow cytometry analysis was performed immediately in an FACS Calibur flow 
cytometer (Becton Dickinson) with an excitation at 488 nm and an emission at 620 nm. 
(Data was produced by Dr. Roger Smith) 
 
 
PXR expression in colon cancer cells inhibited E2F1 and Rb expression 
The Rb/E2F pathway is one of the most important pathways for progression 
through the G1 phase of the cell cycle. When Rb is phosphorylated E2F is released from 
the combined complex and binds to DNA for transcriptional regulation. The result of 
immuno-histochemical staining in the xenograft tumors (corn oil treated tumors) showed 
that E2F1 is strongly expressed in Vector-HT29 tumors but only weakly expressed in 
PXR-HT29 tumors and is located in the nucleus of cancer cells (Figure 21A, upper 
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panel). There is a significant difference between the positive cell ratios of the two groups 
(Figure 21C, 35.0% ± 3.9 vs. 9.8% ± 1.9, p<0.01). Rb expression is also located in the 
nucleus of cancer cells (Figure A lower panel) and markedly decreased in PXR-HT29 
tumors as compared to Vector-HT29 (Figure 21D, 26.2% ± 5.7 vs. 75.6% ± 10.4, 
p<0.01). Western blot analysis further confirmed the differential expression of E2F1 and 
Rb in the tumors from both groups (Figure 21B). 
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FIGURE 21: Analysis of xenograft tissues indicate that E2F1 and Rb levels are 
decreased in PXR positive tumors. Immuno-histochemical staining was performed in 
HT-29 tumors removed from the nude mice. Paraffin-embedded sections were 
deparaffinized, rehydrated, and microwave heated for antigen retrieval. After 15 minutes 
of blocking with normal serum, the primary antibody or corresponding control isotype 
IgG were applied and incubated overnight at 4°C. Slides were washed and the 
biotinylated secondary antibody and the streptavidin-biotin complex were applied, each 
for 30 minutes at room. After rinsing with PBS, the slides were immersed for 10 minutes 
in 3,3'-diaminobenzidine solution, monitored under microscope and the reaction was 
stopped with distilled water, then counterstained with hematoxylin, dehydrated, and 
coverslipped. Western blot was performed to confirm the presence of proteins seen in 
immuno-histochemical staining. Anti-β-tubulin was used as the protein level control. 
(Immuno-histochemistry conducted by Nengtai Ouyang) 
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DISCUSSION AND CONCLUSION 
 
The human body deals with xenobiotics and drugs in an evolutionarily conserved 
process and is continuously shaped by gene-environment interaction.  The human 
population continues to grow which increases our need for medications to combat 
disease and thus a more complete understanding of drug-drug interactions and adverse 
effects is required. Cytochrome P450 3A4 is a key drug metabolizing enzyme that is 
responsible for metabolism of over fifty percent of clinical medications. The pregnane X 
receptor, a member of the nuclear receptor super family, is a transcriptional regulator of 
CYP3A4 expression. PXR responds to endogenous and exogenous ligands.  Our 
laboratory has been investigating the mechanism of PXR-regulated gene expression.  
The pregnane X receptor directly interacts with CNOT2 to affect cytochrome P450 
3A4 expression 
In order to determine protein partners of PXR we screened the human cDNA 
library by yeast two-hybrid assay. Over one million independent clones were screened. 
One of the positive clones was a partial fragment of the C-terminal end of CNOT2. 
CNOT2 is the second and smallest protein component of the CCR4-NOT complex. The 
CCR4-NOT complex is an evolutionary conserved complex involved in most biological 
processes due to the promiscuity of protein interactions that the components of the 
complex conducts. One important function of the CCR4-NOT complex is RNA 
modification through deadenylation of poly(A) tails. However, the NOT components of 
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the complex are not responsible for this function; Traditionally the NOT components are 
involved in transcriptional regulation as co-activators or co-repressors.   
Previously published reports indicate the NOT box and conserved domains of 
CNOT2 are the domains responsible for protein interactions (Albert et al, 2000; Zwartjes 
et al, 2006).  We were able to verify this with respect to PXR. PXR ligand binding 
domain directly interacts with the NOT box and conserved domains of CNOT2. To 
verify the interaction in mammalian cells we performed mammalian two-hybrid assay 
and co-immunoprecipitation assay. Luciferase reporter gene assay and CNOT2 siRNA 
knock down indicate that when PXR-CNOT2 interact. These results demonstrate that 
PXR and CNOT2 interact to suppress PXR-regulated gene expression. 
We have attempted to verify the location of PXR-CNOT2 interaction. Previously 
published literature indicated that components of CCR4-NOT complex colocalized in 
Cajal bodies (Wagner et al, 2007). Cajal bodies are dynamic structures that form when 
transcription is occurring. We were unable to colocalizes PXR protein and coilin protein 
due to the over expression of PXR. When PXR is over expressed the entire nucleus is 
stained for the target protein. However, we know that PXR can be found in both the 
nucleus and cytoplasm, since the general mechanism of action for PXR involves ligand 
activation in the cytoplasm and subsequent translocation into the nucleus. We should 
have tested cytoplasmic bodies also, for example GW-182 or Dcp16 bodies to determine 
the precise location of PXR-CNOT2 interaction. It is unlikely that PXR and CNOT2 
interact within both the nucleus and cytoplasm.  
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In yeast, CCR4-NOT is the complex primarily responsible for RNA 
modifications. We hypothesized that there might be a role for PXR-CNOT2 in this 
aspect of RNA regulation. In order to test our hypothesis we performed poly(A) tail PCR 
with harvested RNA from HepG2 cells with and without PXR over-expression. There 
was little ligand effect but the results did indicate that less deadenylation occurred in 
cells containing PXR.  
This is an interesting result because it contradicts the early result that PXR-
CNOT2 interact to suppress PXR target gene transcriptional activity. It is possible that 
the cell is trying to expend the least amount of energy and in doing so PXR-CNOT2 has 
a two-sided job. Involvement in RNA modification could be a possible feedback 
mechanism that regulates expression but maintains protein production. CYP3A4 
expression is suppressed at the transcriptional level, but the cell wants to maintain 
translation of the transcripts that were already produced. Due to the importance of 
CYP3A4 enzyme activity the cell does not want to completely repress expression of 
CYP3A4 transcripts. 
Due to restrictions of our lab we were unable to investigate the effects on other 
PXR target genes such as multidrug resistance transporter 1 (MDR1) or other 
cytochrome P450s that influence drug transport and metabolism. It is possible that PXR-
CNOT2 interact at the promoter region to direct splicing of cyp3a. In order to test this 
CNOT2 could be knocked down by siRNA and realtime PCR performed to determine 
the amounts of CYP3A isoforms, CYP3A4, 3A5, 3A7. 
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In conclusion, the first part of experiments conducted in this thesis research 
indicates a new role for PXR beyond transcriptional regulation of its target genes. We 
demonstrated that PXR has a role in post-transcriptional regulation of gene expression 
through interaction with component NOT2 of the CCR4-NOT complex to preserve 
stability of CYP3A4 mRNAs through modulation of deadenylation. 
The pregnane X receptor suppresses colon cancer growth through interaction with 
proteins involved in cell cycle progression 
The second part of the presented research demonstrates that PXR is influential in 
colon cancer progression. Colorectal cancer on average costs a patient $29,196, this 
includes treatment costs, doctor and hospital fees and other costs (Luo et al, 2010). With 
increased colon cancer incidence and mortality it is more important now to determine the 
mechanisms that contribute to colon cancer progression. Clinical efficacy of 
chemotherapy in colorectal cancer is subjected to broad inter-individual variations 
leading to the inability to predict outcome and toxicity; a substantial part of the 
variability observed among patients might be caused by increased expression of PXR 
which results in increased drug metabolism (Raynal et al, 2010).  
Dia et al. (2008) showed that PXR is required for normal liver regeneration. 
From their results the underlying assumption that PXR might be involved in colon 
cancer led us to investigate the role for PXR as a tumor suppressor protein. Our initial 
results showed that transfected PXR gene inhibits cancer cell growth. Hence, the tumor 
suppressor activity of PXR was hypothesized and further investigated in HT29 colon 
cancer cells in vitro and in vivo.   
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The distribution of PXR in the nucleus of most cancer cells is consistent with 
other results that were found in human breast cancer tissue and may implicate functional 
activation of PXR. Initial observations made during routine cell culture indicated that 
cancer cells with PXR expression grew slower. HepG2 (liver carcinoma cells) and HT29 
(colon carcinoma cells) with PXR stable transfection were 3-4 days behind reaching 
confluency of cells without PXR expression. 
 Separate distribution of PXR and Ki-67 further directly confirmed the inhibitory 
activity of PXR to proliferation in HT29 cells. Some studies on PXR have been involved 
in cell proliferation but this effect was mostly considered to be indirectly conducted by 
enhancing detoxification capability of the cells which then decreases cell proliferation by 
metabolizing the chemicals that promote cell proliferation.  Here we report that PXR 
itself directly inhibits colon cancer cell proliferation or tumor growth because the 
principle enzymes that PXR regulates like CYP3A4 and CYP1A1 were not up-regulated 
after PXR transfection (data not shown).  
In conclusion, these results may suggest that the induction of PXR over-
expression in colon cancer cells has potential to be a new approach for tumor therapy. 
Our results suggest that PXR plays a novel biological function of anti-proliferation in 
vitro and in vivo beyond regulation of enzymes responsible for metabolism and 
detoxification. This function may be caused directly by inhibiting cell proliferation 
through Rb/E2F pathway in G1 phase of cell cycle.  
In order to apply our laboratory’s research that PXR expression suppresses tumor 
growth one would need to weigh the differences in benefits of the available treatments. 
 
 
63 
Our results might be better suited to be applied as a preventive measure prior to 
identification of colorectal cancer and treatment by chemotherapeutics. For example, St. 
John’s Wort is an effective ligand of PXR and therefore could be successfully utilized to 
increase PXR expression, in affect to suppress pre-cancerous colon cells. Yet again the 
problem arises of drug-drug interactions; if you are taking any other medications that are 
metabolized through PXR target genes taking a PXR ligand would also increase the 
metabolism of that medication. 
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